Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Gains from Investment Securities (2016 - 2025)

Medifast (MED) has disclosed Gains from Investment Securities for 16 consecutive years, with $11.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 832.18% year-over-year to $11.5 million, compared with a TTM value of $10.5 million through Dec 2025, down 67.99%, and an annual FY2025 reading of $10.5 million, up 747.19% over the prior year.
  • Gains from Investment Securities was $11.5 million for Q4 2025 at Medifast, up from -$606000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $34.9 million in Q4 2023 and bottomed at -$41.3 million in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $1.1 million, with a median of -$62000.0 recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 9931.76% in 2021, while the deepest fall reached 22347.83% in 2021.
  • Year by year, Gains from Investment Securities stood at -$41.3 million in 2021, then surged by 94.84% to -$2.1 million in 2022, then skyrocketed by 1737.42% to $34.9 million in 2023, then tumbled by 104.49% to -$1.6 million in 2024, then skyrocketed by 832.18% to $11.5 million in 2025.
  • Business Quant data shows Gains from Investment Securities for MED at $11.5 million in Q4 2025, -$606000.0 in Q3 2025, and -$8000.0 in Q2 2025.